fibrosis/fatigue

TECHNICAL FIELD The present inventions relate generally to compositions, kits, and methods for the treatment of intestinal hyperpermeability. BACKGROUND The intestinal epithelium separates luminal contents from the interstitium. This function is primarily determined by the integrity of the

TECHNICAL FIELD The present inventions relate generally to compositions, kits, and methods for the treatment of intestinal hyperpermeability. BACKGROUND The intestinal epithelium separates luminal contents from the interstitium. This function is primarily determined by the integrity of the

TECHNICAL FIELD The present inventions relate generally to compositions, kits, and methods for the treatment of intestinal hyperpermeability. BACKGROUND The intestinal epithelium separates luminal contents from the interstitium. This function is primarily determined by the integrity of the

TECHNICAL FIELD The present inventions relate generally to compositions, kits, and methods for the treatment of intestinal hyperpermeability. BACKGROUND The intestinal epithelium separates luminal contents from the interstitium. This function is primarily determined by the integrity of the

TECHNICAL FIELD The present inventions relate generally to compositions, kits, and methods for the treatment of intestinal hyperpermeability. BACKGROUND The intestinal epithelium separates luminal contents from the interstitium. This function is primarily determined by the integrity of the

TECHNICAL FIELD The present inventions relate generally to compositions, kits, and methods for the treatment of intestinal hyperpermeability. BACKGROUND The intestinal epithelium separates luminal contents from the interstitium. This function is primarily determined by the integrity of the

BACKGROUND OF INVENTION It is currently believed that the diseases known as "autoimmune" diseases are caused by the body's immune system attacking the body itself. But I have discovered that these so-called "autoimmune" diseases are actually caused by stealthy intra-cellular bacteria. I have

FIELD OF THE INVENTION The present invention relates to novel isolated strains of Bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (TER) of a Caco-2 cell monolayer after 10 h treatment to more than 120% of TER at treatment start, ii) inducing

TECHNICAL FIELD The invention relates to the milk protein A2 beta-casein and improving the antioxidant capacity in an animal by increasing the levels of glutathione in the body of the animal. In particular, the invention relates to milk and milk derived food products. The applicant has found that